<DOC>
	<DOCNO>NCT00738751</DOCNO>
	<brief_summary>The main purpose study : - Determine safety tolerability erlotinib LBH589B . - Establish recommend phase II expansion dose LBH589B erlotinib patient advance aerodigestive tract cancer .</brief_summary>
	<brief_title>Phase I Study LBH589 &amp; Erlotinib Advanced Aerodigestive Tract Cancers</brief_title>
	<detailed_description />
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<criteria>Histologically cytologically document diagnosis advanced/metastatic NSCLC Head Neck cancer . Male female patient age ≥ 18 year old Ability provide write informed consent obtain prior participation study relate procedure perform Have progressive measurable disease measure Response Evaluation Criteria Solid Tumors ( RECIST ) criterion Patients must discontinue prior systemic chemotherapy 14 day . Patients must meet follow laboratory criterion : 1 . Serum albumin ≥ 3g/dL 2 . Aspartic transaminase ( AST/SGOT ) alanine transaminase ( ALT/SGPT ) ≤ 2.5 x upper limit normal ( ULN ) ≤ 5.0 x ULN transaminase elevation due leukemic involvement 3 . Serum bilirubin ≤ 1.5 x ULN 4 . Serum creatinine ≤ 1.5 x ULN 24hour creatinine clearance ≥ 50 ml/min 5 . Serum potassium ≥ low limit normal ( LLN ) ≤ ULN 6 . Serum phosphorous ≥ LLN 7 . Serum total calcium ( correct serum albumin ) serum ionized calcium ≥ LLN 8 . Serum magnesium ≥ LLN 9 . Absolute neutrophil count ( ANC ) ( ANC : segmented band ) ≥ 1.5 X10^9/L 10 . Platelets ≥ 100 X 10^9/L Baseline multiple gate acquisition imaging ( MUGA ) echocardiogram ( ECHO ) must demonstrate leave ventricular ejection fraction ( LVEF ) ≥ low limit institutional normal Eastern Cooperative Oncology Group ( ECOG ) Performance Status ≤ 1 Reproductive potential must either terminate ( surgery , radiation , menopause ) attenuate use approve contraceptive method 3 6 month follow study . Patient instruct intravenous ( IV ) bisphosphonates withhold first 8 week LBH589 therapy due risk hypocalcemia . Impaired cardiac function include one following : 1 . Screening electrocardiogram ( ECG ) correct QT ( QTc ) &gt; 450 msec confirm central laboratory prior enrollment study 2 . Patients congenital long QT syndrome 3 . History sustain ventricular tachycardia 4 . Any history ventricular fibrillation torsades de point 5 . Bradycardia define heart rate &lt; 50 beat per minute . Patients pacemaker heart rate ≥ 50 beat per minute eligible . 6 . Patients myocardial infarction unstable angina within 6 month study entry 7 . Congestive heart failure New York Heart Association ( NYHA ) class III IV 8 . Right bundle branch block leave anterior hemiblock ( bifascicular block ) 9 . Patients history uncontrolled chronic atrial fibrillation . Uncontrolled hypertension , blood pressure ( BP ) &gt; 180/110 3 separate occasion despite oral antihypertensive medication Concomitant use drug risk cause torsades de pointes Concomitant use CYP3A4 inhibitor Patients documented central nervous system leptomeningeal metastasis ( brain metastasis ) time study entry . Patients prior brain metastasis may consider complete treatment brain metastasis , long require corticosteroid , asymptomatic . Patients unresolved diarrhea &gt; Common Terminology Criteria Adverse Events ( CTCAE ) grade 1 Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption oral LBH589 Other concurrent severe and/or uncontrolled medical condition Patients receive chemotherapy &lt; 14 day , investigational drug &lt; 14 day undergone major surgery &lt; 4 week prior start study drug recover side effect therapy . Concomitant use anticancer therapy ( except erlotinib ) radiation therapy . Female patient pregnant breast feed patient reproductive potential use two effective method birth control . Women childbearing potential ( WOCBP ) must negative serum pregnancy test within 7 day first administration oral LBH589 Male patient whose sexual partner WOCBP use effective birth control Patients know positivity human immunodeficiency virus ( HIV ) hepatitis C ; baseline test HIV hepatitis C require Patients significant history noncompliance medical regimen inability grant reliable informed consent Patients willing refrain wear contact lens study participation exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>Metastatic</keyword>
	<keyword>erlotinib</keyword>
	<keyword>aerodigestive tract cancer</keyword>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>H &amp; N cancer</keyword>
</DOC>